Oscient Pharmaceuticals (OSCI) Misses Q1 EPS by 12c, Receives FDA Approval for FACTIVE Five-Day Treatment of Community-Acquired Pneumonia
More News related to OSCI
- Oscient Pharmaceuticals (OSCI) Discontinues Direct Selling of its Products; Eliminates 150-Person Sales Force
- Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVE
- Oscient Pharmaceuticals Receives NASDAQ Letter Regarding Delay in Filing Form 10-Q
- Oscient Pharmaceuticals Files Form 12b-25 Notification of Late Filing for Form 10-Q for Quarterly Period Ended March 31, 2009
- Oscient Pharma (OSCI) Reports Smaller Q4 Loss
Oscient Pharmaceuticals Corp. (Nasdaq: OSCI) reports a Q1 loss of $0.88, 12 cents worse than estimates. Revenues were $23.2 million vs. $23.09 million consensus.
Separately, The U.S. Food and Drug Administration (FDA) has approved Oscient Pharmaceuticals' FACTIVE tablets for the five-day treatment of community-acquired pneumonia of mild to moderate severity (CAP). The approved supplemental New Drug Application (sNDA) was based on the results of the Company's successful Phase III trial in 510 CAP patients comparing a five-day treatment and the originally approved seven-day treatment with FACTIVE 320 mg once-daily.
Related Categories
EarningsFDA
Stocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
